CHMP recommends once-weekly Sogroya to treat growth hormone deficiency – Novo Nordisk
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion for the use of once-weekly Sogroya (somapacitan), recommending marketing authorisation for the treatment of adults with growth hormone deficiency (AGHD).
The CHMP recommends once-weekly Sogroya (somapacitan) to be indicated for the replacement of endogenous growth hormone in adults with AGHD. Sogroya (somapacitan) is a new long-acting human growth hormone therapy that is taken once a week by injection under the skin. This recommendation is based on the results from REAL 1, a clinical trial programme investigating the efficacy and safety of Sogroya (somapacitan) in adults with growth hormone deficiency.